Drug intelligence / Profile preview

nonivamide + nicoboxil

Development stage
Phase 3
Lead developer
Boehringer Ingelheim
Modality
Small Molecules
Administration
Topical
01

Overview

Nonivamide + nicoboxil is a fixed-dose topical rubefacient analgesic marketed as **Finalgon** in certain countries. Nonivamide is a synthetic capsaicinoid that activates transient receptor potential cation channel subfamily V member 1 on cutaneous nociceptive sensory neurons, producing local warmth, neurogenic vasodilation, and subsequent analgesic desensitization. Nicoboxil is a nicotinic-acid ester with prostaglandin-mediated vasodilatory activity that accelerates and intensifies local hyperemia. The combination has been used for musculoskeletal pain and was evaluated in completed Phase III studies for acute nonspecific low back pain. ([drugs.ncats.io](https://drugs.ncats.io/drug/GSD5B9US0W))

Brand names
Finalgon
Other names
nicoboxil + nonivamidnicoboxil + nonivamidenicoboxil/nonivamidenonivamid + nicoboxilnonivamide/nicoboxil
02

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on nonivamide + nicoboxil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on nonivamide + nicoboxil.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call